mRNA-1982 Vaccine for Lyme Disease

This trial tests a new mRNA vaccine designed to prevent Lyme disease, a tick-borne illness that can cause flu-like symptoms and joint pain. The study aims to determine the optimal dose, evaluate the vaccine's effectiveness, and assess its safety. Participants will receive either the mRNA vaccine or a placebo via injection. Ideal candidates are healthy adults who have not recently undergone Lyme disease treatment or received any Lyme disease vaccines. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

An earlier study found the mRNA-1982 vaccine for Lyme disease to be generally safe. The research showed no serious side effects, with no major health issues reported. Some participants experienced mild symptoms such as rash, fever, headaches, tiredness, and joint pain. These common vaccine reactions typically resolve on their own. Now in Phase 2 trials, this treatment has already passed at least one human study, indicating it is well-tolerated so far.¹²³⁴⁵

Unlike traditional vaccines for Lyme disease, which often use inactivated or attenuated bacteria, the mRNA-1982 vaccine harnesses the power of mRNA technology. This means it teaches the body to produce a protein from the Lyme-causing bacteria, prompting an immune response without using the actual bacteria. Researchers are excited because this approach can potentially offer a more precise and adaptable response, reducing the risk of side effects and potentially improving efficacy. Additionally, the mRNA platform allows for quicker updates to the vaccine if the pathogen changes over time.

Research has shown that past Lyme disease vaccines, which targeted specific parts of the bacteria, provided strong protection by triggering the body's defense system. Early results from studies on the mRNA-1982 vaccine, currently tested in this trial, indicate it can safely activate the immune system. Other studies have demonstrated that vaccines targeting six different strains of Lyme disease have been over 70% effective in preventing the illness. Initial signs also indicate that mRNA-based vaccines can boost immune protection without causing serious side effects. These findings suggest that mRNA-1982 could effectively prevent Lyme disease.¹²³⁵⁶